Market Overview

UPDATE: Morgan Stanley Raises PT to $83 on Celgene on Abraxane-Driven Growth Outlook

Related CELG
Concert Pharmaceuticals Announces $8 Million Milestone from Celgene
Biotech Bears Spark Good Vibes For These ETFs
Why We Should Take This Biotech Selloff Seriously (Seeking Alpha)

Morgan Stanley reiterated its Overweight rating on Celgene (NASDAQ: CELG) and raised its price target from $81 to $83.

Morgan Stanley commented, "Details are scant prior to an ASCO GI data presentation (1/24-26) but we are optimistic about a clinically relevant ~1.5-2 month or better median OS benefit. For the stock, this outcome is important as Abraxane with pomalidomide and apremilast can provide much needed growth diversification away from Revlimid. … Incorporating Abraxane in pancreatic cancer into our model with ~$700MM in 2020 revenue pending the detailed Phase III data and our price target rises to $83 from $81. We assume modest off-label use in the US (already compendia listed) begins in 2013."

Celgene closed at $71.50 on Friday.

Latest Ratings for CELG

Oct 2015JPMUpgradesNeutralOverweight
Sep 2015JefferiesInitiates Coverage onBuy
Jul 2015Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (CELG)

View Comments and Join the Discussion!

Get Benzinga's Newsletters